Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?
Pharmacopsychiatry
; 47(1): 33-6, 2014 Jan.
Article
em En
| MEDLINE
| ID: mdl-24127329
ABSTRACT
Despite progress made in the treatment of tobacco dependence, currently available treatments are effective for only a fraction of smokers. The aim of this study was to evaluate the association between the effectiveness of treatment with nicotine or bupropion in heavy smokers (n=70), and 6 candidate polymorphisms in CYP2A6, 5-HTT and HTR2A genes. Analysis revealed a significant association between "favourable" genotype combination carriers (CYP2A6 "slow metabolizer" or 5HTT L-allele or HTR2A-1438GG) and nicotine treatment outcome (OR=2.69, 95% CI=1.28-5.64). Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
Tabagismo
/
Hidrocarboneto de Aril Hidroxilases
/
Abandono do Hábito de Fumar
/
Receptor 5-HT2A de Serotonina
/
Proteínas da Membrana Plasmática de Transporte de Serotonina
Tipo de estudo:
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article